ArticleVirology journal2025
The emergence of a highly pathogenic marek's disease virus featuring newly identified mutations in Meq oncogene in Southern China.
Article in Virology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Grafting of Md5 gC onto herpesvirus of turkeys confers full protection against very virulent Marek's disease virus.Poultry science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundMarek's disease virus (MDV) is a significant threat to global poultry health, causing high mortality, tumor formation, and severe immunosuppression, leading to substantial economic losses. Continuous monitoring and research on MDV field strains are essential for developing effective vaccination strategies and biosafety measures.
methodsIn this study, peripheral blood was collected from a chicken farm in southern China where an outbreak of MDV occurred despite vaccination with the CVI988 vaccine. A virulent field strain of MDV was isolated and identified through plaque purification experiments, PCR, and indirect immunofluorescence assays. The molecular characteristics of the Meq gene were analyzed by cloning and sequencing. Finally, animal experiments were conducted to evaluate the pathogenicity, oncogenicity, and vaccine protective efficacy of the isolated strain.
resultsA highly pathogenic MDV strain, designated as SS1901, was isolated and purified from a chicken farm vaccinated with CVI988. Sequencing of the oncogenic protein Meq revealed mutations at K77E, D80Y, V115A, T139A, P176R, and P217A, consistent with mutations found in other prevalent Chinese strains. Additional mutations at A88T and Q93R were identified, which have been observed in MDV strains from southern China, India, and Italy, indicating the circulation of such strains. Challenge protection experiments demonstrated that SS1901 caused 100% mortality and 80% tumor incidence in SPF chickens, with tumors primarily in the heart, spleen, and liver. HVT, 814 and CVI988 vaccines provided 46.7%, 80% and 73.3% protection, respectively. Combination of CVI988 and HVT rendered the highest protection at 86.7%.
conclusionsThis study reports new mutation sites in the Meq gene of a prevalent Chinese MDV strains and confirms the isolate SS1901 could overcome existing vaccine-induced immunity, providing valuable new information for monitoring new MDV field strains and developing novel control strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.